Moderna, Inc. (MRNA)
|Net Income (ttm)||14.06B|
|Day's Range||180.09 - 190.28|
|52-Week Range||115.61 - 497.49|
|Price Target||225.08 (+23.0%)|
|Earnings Date||Aug 3, 2022|
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus... [Read more...]
Financial PerformanceFinancial Statements
According to 26 analysts, the average rating for MRNA stock is "Buy." The 12-month stock price forecast is 225.08, which is an increase of 23.03% from the latest price.
MRNA vs. TECH: Which Stock Is the Better Value Option?
COVID vaccine manufacturer Moderna's CEO discusses the company's Q3 earnings
Moderna CEO Stéphane Bancel discusses the reasons behind the company's Q3 success, and his anticipations for Q4. Segment originally aired on August 3, 2022.
Your portfolio is counting on you to pass the tests.
The biotech's fortunes could reverse.
Moderna CEO discusses COVID-19 risks, vaccine boosters, MRNA technology and more
Moderna CEO Stéphane Bancel sat down with Yahoo Finance's Anjalee Khemlani to discuss what's been happening with their covid booster, meeting global vaccine demand, and what other medical areas the comp...
Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in its...
A combination of solid earnings and investor optimism has many of the year's losers seeing some gains.
Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program.
Moderna CEO: ‘We are seeing very strong' vaccine demand
Moderna CEO Stéphane Bancel speaks with Yahoo Finance's Anjalee Khemlani about earnings, COVID-19 vaccine demand, the biotech company's pipeline, and monkeypox vaccine development.nce
Investors are cheering the company's Q2 results. But there was a troubling detail in Moderna's update.
Moderna stock gets boost from earnings beat, COVID-19 vaccine sales
Yahoo Finance's Anjalee Khemlani discusses second-quarter earnings for Moderna, the Biden administration's fall booster campaign, COVID-19 vaccine sales, and longer-term vaccine growth.
MRNA) research Coronavirus (Covid 19) vaccine. Row of vaccine bottles with blurred Moderna company logo on background.
Moderna (MRNA) delivered earnings and revenue surprises of 16.44% and 22.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Moderna stock jumped Wednesday after sales of the company's Covid vaccine and earnings easily outperformed expectations. The post Moderna Stock Surges After Covid Vaccine Sales Obliterate Expectations a...
Moderna took a nearly $500 million hit on write-downs for vaccine inventory that has expired or is expected to expire before is can be used.
Shares of Moderna Inc. MRNA, -0.43% gained 3.8% in premarket trading on Wednesday after the company beat earnings and revenue expectations in the second quarter of the year. Moderna had net income of $2...
Moderna Inc on Wednesday maintained its full-year sales outlook for its COVID-19 vaccine, following a similar prediction by bigger rival Pfizer Inc a week ago, amid tepid demand from low-to-middle incom...
Second quarter 2022 revenues of $4.7 billion; GAAP net income of $2.2 billion and GAAP diluted EPS of $5.24 Company reiterates advance purchase agreements for expected delivery in 2022 of approximately ...
The booster market might be a long-term source of revenue.
Moderna is still prevailing in the omicron booster market in at least one important way.
Platforms are out.
Moderna's blockbuster product is set for a new wave of demand.
The biotech keeps up a steady supply of coronavirus vaccine boosters to a very reliable customer.